Anti-tumor innovative biopharmaceutical developer “Mori Life” pushes the project into clinical stage
“原力生命科学” Official website shows that IONOVA LIFE SCIENCE CO., LTD. has completed RMB 126 million Series A financing. The investment leader is the Lilly Asia Fund, and the angel round invests in the German capital.
“Lori Life” is an innovative biomedical research and development company located in Dawan District, Guangdong, Hong Kong and Macau. It is mainly engaged in the research and development and production of new drugs, and its business covers oncology, immuno-oncology, and other therapeutic areas. At present, the company’s business strategy is to introduce a highly differentiated, diversified (including small molecule and macromolecular), balanced tumor drug through internal research and development, combined with cross-border strategic cooperation, acquisition and special licensing. R & D pipelines, and ultimately turn them into innovative anti-tumor products, unmet medical needs for patients.
Ping An Securities pointed out in its “In-depth analysis of anti-tumor targeted drugs in the bio-pharmaceutical industry” that in 2015, there were 4.29 million new cancer patients in China, and the six highest prevalence rates were lung cancer, stomach cancer, and esophageal cancer. , liver cancer, colorectal cancer, breast cancer. Due to the lack of tumor screening and the lack of effective drugs, Chinese cancer patients have a high mortality rate. With the progress of aging, the rising incidence, and the promotion of policies, cancer has become a public issue. The demand for cancer diagnosis and treatment drugs is very strong, and the market space for anti-tumor drugs in the next 10 years is very impressive.
At present, the “Benli Life” project is more focused on the early development, optimization and IND R&D and reporting of anti-cancer drugs. The founder, Dr. Sun Yongkui, said that the financing will promote the transformation of the Force’s preclinical projects into the clinical stage and will continue to promote the company’s research and development pipeline.
The founding team of “Benli Life” includes scientists and senior business executives who have been engaged in innovative drug research and development in multinational companies for a long time. Founder, Chairman and CEO Dr. Sun Yongkui, was named a Fellow of the National Academy of Engineering in 2016 and worked at Mussa East A medical organization headquartered in the United States that specializes in the development, manufacture and operation of vaccines and pharmaceuticals for more than 20 years. It has a wealth of experience in new drug development and business development. The core members of the team include Dr. He Guoqin, vice president of research and development. He previously worked for Eli Lilly and Pharmaceutical Co., Ltd.; and other senior executives who have held senior positions in several group companies such as Sanofi and Pengrun Investment.
Image source: pexels